Neuronetics, Inc.
STIM- 1M
- -27.8%
Neuronetics, Inc. in brief
Neuronetics, Inc. is a listed company in the Diagnostics and Research industry, based in Malvern, Pennsylvania, USA. It was founded in 2003. Its market value was $162 M on 23 October 2026, which makes it the 17,042nd largest listed company in the world and the 3,274th largest in the USA on this site. In the year to December 2025 it had sales of $149 M and a net loss of $39 M. Daniel L. Reuvers is its chief executive. Its largest business segments by sales in 2025 were Clinical Services (58%) and Medical Device (42%). Its shares trade under the symbol STIM (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Neuronetics, Inc.
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became the "first and only Food and Drug Administration (FDA) approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device (FDA approval K061053)."
They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Neuronetics, Inc. timeline
- 2003
- 🏁· approximateFounded
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2018
- •Legal Entity Identifier issuedLEI 549300T0911ILTTG7P06 registered.
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 29 June 2018; shares registered for exchange trading on 19 June 2018.
- 2025
- 💰Record revenue of $149 millionFY2025, the highest of the 8 years on record.
Events of Neuronetics, Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,820 (Jan 2020) · #3,192 (Jan 2021) · #4,418 (Jan 2022) · #3,869 (Dec 2022) · #4,654 (Jul 2023) · #3,855 (Jan 2024) · #1,947 (Mar 2026) · #2,977 (Aug 2026) · #3,065 (Sep 2026) · #3,278 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.0×
- Price / book
- 7.2×
- Free cash flow yield
- -13.1%
- Net margin (TTM)
- -14.4%
- Operating margin
- -21.1%
- Return on equity
- -103.1%
- Liabilities / assets
- 81.5%
- Net debt
- $38M
- Revenue growth
- +99.2%
- R&D / revenue
- 4.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $149M | +99.2% | $-31M | $-39M | -26.1% |
| Dec 2024 | $75M | +5.0% | $-35M | $-44M | -58.4% |
| Dec 2023 | $71M | +9.4% | $-31M | $-30M | -42.3% |
| Dec 2022 | $65M | +17.9% | $-35M | $-37M | -57.0% |
| Dec 2021 | $55M | +12.3% | $-28M | $-31M | -56.4% |
| Dec 2020 | $49M | -21.4% | $-22M | $-27M | -55.7% |
| Dec 2019 | $63M | +18.7% | $-27M | $-29M | -46.3% |
| Dec 2018 | $53M | — | $-20M | $-24M | -45.7% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-20M | $1M | $-21M | $-0.59 | — |
| Dec 2024 | $-31M | $1M | $-32M | $-1.38 | — |
| Dec 2023 | $-32M | $2M | $-34M | $-1.05 | — |
| Dec 2022 | $-31M | $3M | $-34M | $-1.38 | — |
| Dec 2021 | $-28M | $2M | $-30M | $-1.22 | — |
| Dec 2020 | $-28M | $1M | $-29M | $-1.46 | — |
| Dec 2019 | $-30M | $1M | $-31M | $-1.58 | — |
| Dec 2018 | $-21M | $1M | $-22M | $-2.69 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $42M (+12.5% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 20268-K/ACurrent report (amended)Material agreement · Other events
- Nov 12, 20268-KCurrent reportMaterial agreement · Other events
- Nov 10, 20268-KCurrent reportMaterial agreement
- Nov 4, 202610-QQuarterly report · period to Sep 2026
- Nov 4, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Aug 17, 20268-KCurrent reportDirectors or officers changed
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations · Regulation FD disclosure
- Jul 20, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Jun 23, 20268-KCurrent reportDirectors or officers changed
- May 29, 20268-KCurrent reportShareholder vote
- May 22, 20268-KCurrent reportDirectors or officers changed
Official filings of Neuronetics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $149 M
- Operating income
- $-31 M
- Net income
- $-39 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $142 M
- Total liabilities
- $115 M
- Total equity
- $22 M
As of December-2025
Top 96 institutional investors in Neuronetics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Madryn Asset Management, LP | 18,540,488 | 0 (0.00%) | 23.85% | $43 M | Nov 12, 2026 |
| 2 | Point72 Asset Management, L.P. | 4,163,261 | New | 5.36% | $10 M | Nov 16, 2026 |
| 3 | Wexford Capital LP | 2,002,625 | 0 (0.00%) | 2.58% | $5 M | Nov 13, 2026 |
| 4 | Marshall Wace, LLP | 1,551,840 | +1,066,148 (+219.51%) | 2.00% | $4 M | Nov 13, 2026 |
| 5 | Vanguard Capital Management LLC | 1,527,373 | +20,276 (+1.35%) | 1.97% | $4 M | Nov 13, 2026 |
| 6 | Eversept Partners, LP | 1,402,548 | New | 1.80% | $3 M | Nov 16, 2026 |
| 7 | Lane Generational LLC | 1,262,179 | -371,193 (-22.73%) | 1.62% | $3 M | Nov 9, 2026 |
| 8 | HighTower Advisors, LLC | 1,101,502 | +537,761 (+95.39%) | 1.42% | $3 M | Nov 10, 2026 |
| 9 | Masters Capital Management LLC | 1,000,000 | 0 (0.00%) | 1.29% | $2 M | Nov 16, 2026 |
| 10 | FourWorld Capital Management LLC | 937,401 | -806,741 (-46.25%) | 1.21% | $2 M | Nov 16, 2026 |
| 11 | AdvisorShares Investments LLC | 924,380 | +181,585 (+24.45%) | 1.19% | $2 M | Nov 9, 2026 |
| 12 | Ikarian Capital, LLC | 810,182 | +109,000 (+15.55%) | 1.04% | $2 M | Nov 16, 2026 |
| 13 | Morgan Stanley | 753,323 | +690,430 (+1097.79%) | 0.97% | $2 M | Nov 13, 2026 |
| 14 | Citadel Advisors LLC | 639,774 | +217,871 (+51.64%) | 0.82% | $1 M | Nov 16, 2026 |
| 15 | Driehaus Capital Management LLC | 580,549 | New | 0.75% | $1 M | Nov 16, 2026 |
| 16 | UBS Group AG | 573,630 | -1,705,469 (-74.83%) | 0.74% | $1 M | Nov 10, 2026 |
| 17 | Geode Capital Management, LLC | 480,396 | +21,922 (+4.78%) | 0.62% | $1 M | Nov 6, 2026 |
| 18 | D. E. Shaw & Co., Inc. | 461,710 | New | 0.59% | $1 M | Nov 16, 2026 |
| 19 | BlackRock, Inc. | 452,618 | -144,004 (-24.14%) | 0.58% | $1 M | Nov 13, 2026 |
| 20 | Squarepoint Ops LLC | 435,951 | +341,335 (+360.76%) | 0.56% | $1 M | Nov 9, 2026 |
| 21 | Renaissance Technologies LLC | 424,400 | New | 0.55% | $1 M | Nov 12, 2026 |
| 22 | Millennium Management LLC | 342,434 | +142,984 (+71.69%) | 0.44% | $1 M | Nov 16, 2026 |
| 23 | Diametric Capital, LP | 323,452 | New | 0.42% | $1 M | Nov 16, 2026 |
| 24 | State Street Corp | 302,699 | +12,400 (+4.27%) | 0.39% | $1 M | Nov 12, 2026 |
| 25 | Boothbay Fund Management, LLC | 281,367 | +92,104 (+48.66%) | 0.36% | $1 M | Nov 16, 2026 |
Show all 96: investors 26 to 96
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Balyasny Asset Management L.P. | 255,020 | New | 0.33% | $1 M | Nov 16, 2026 |
| 27 | Goldman Sachs Group Inc | 253,004 | -11,084 (-4.20%) | 0.33% | $1 M | Nov 16, 2026 |
| 28 | HRT Financial LP | 251,721 | +163,011 (+183.76%) | 0.32% | $1 M | Nov 13, 2026 |
| 29 | Jane Street Group, LLC | 239,475 | +54,225 (+29.27%) | 0.31% | $1 M | Nov 12, 2026 |
| 30 | Vanguard Fiduciary Trust Co | 239,190 | -25,544 (-9.65%) | 0.31% | $1 M | Nov 13, 2026 |
| 31 | Quadrature Capital Ltd | 214,351 | +183,495 (+594.68%) | 0.28% | $1 M | Nov 13, 2026 |
| 32 | BRC Group Holdings, Inc. | 200,000 | New | 0.26% | $0 M | Nov 13, 2026 |
| 33 | Bank of New York Mellon Corp | 176,317 | New | 0.23% | $0 M | Nov 5, 2026 |
| 34 | XTX Topco Ltd | 108,274 | -112,049 (-50.86%) | 0.14% | $0 M | Nov 16, 2026 |
| 35 | Bank Of America Corp /de/ | 102,753 | +34,558 (+50.68%) | 0.13% | $0 M | Nov 16, 2026 |
| 36 | ADAR1 Capital Management, LLC | 100,000 | 0 (0.00%) | 0.13% | $0 M | Nov 16, 2026 |
| 37 | Northern Trust Corp | 93,902 | +4,764 (+5.34%) | 0.12% | $0 M | Nov 16, 2026 |
| 38 | Bridgeway Capital Management, LLC | 90,305 | -4,900 (-5.15%) | 0.12% | $0 M | Nov 16, 2026 |
| 39 | Empowered Funds, LLC | 90,305 | New | 0.12% | $0 M | Nov 13, 2026 |
| 40 | Susquehanna International Group, LLP | 87,632 | -98,121 (-52.82%) | 0.11% | $0 M | Nov 16, 2026 |
| 41 | Canada Pension Plan Investment Board | 80,500 | New | 0.10% | $0 M | Nov 16, 2026 |
| 42 | GAMCO Investors, Inc. Et Al | 79,200 | 0 (0.00%) | 0.10% | $0 M | Nov 12, 2026 |
| 43 | Jefferies Financial Group Inc. | 75,000 | New | 0.10% | $0 M | Nov 5, 2026 |
| 44 | Dauntless Investment Group, LLC | 69,228 | -299,959 (-81.25%) | 0.09% | $0 M | Nov 16, 2026 |
| 45 | Centiva Capital, LP | 63,184 | -222,729 (-77.90%) | 0.08% | $0 M | Nov 13, 2026 |
| 46 | VestGen Advisors, LLC | 50,200 | -79 (-0.16%) | 0.06% | $0 M | Oct 27, 2026 |
| 47 | Cruiser Capital Advisors, LLC | 48,900 | 0 (0.00%) | 0.06% | $0 M | Nov 16, 2026 |
| 48 | Tudor Investment Corp Et Al | 48,343 | -76,518 (-61.28%) | 0.06% | $0 M | Nov 16, 2026 |
| 49 | Allworth Financial LP | 45,756 | +45,587 (+26974.56%) | 0.06% | $0 M | Nov 17, 2026 |
| 50 | Invesco Ltd. | 42,228 | -26,112 (-38.21%) | 0.05% | $0 M | Nov 12, 2026 |
| 51 | Arax Advisory Partners | 39,417 | -426 (-1.07%) | 0.05% | $0 M | Nov 12, 2026 |
| 52 | T3 Companies, LLC | 37,600 | New | 0.05% | $0 M | Oct 22, 2026 |
| 53 | Virtu Financial LLC | 37,289 | +7,707 (+26.05%) | 0.05% | $0 M | Nov 17, 2026 |
| 54 | Engineers Gate Manager LP | 35,953 | -21,222 (-37.12%) | 0.05% | $0 M | Nov 16, 2026 |
| 55 | JBF Capital, Inc. | 33,166 | -200,000 (-85.78%) | 0.04% | $0 M | Nov 16, 2026 |
| 56 | Two Sigma Securities, LLC | 30,004 | New | 0.04% | $0 M | Nov 16, 2026 |
| 57 | Jump Financial, LLC | 29,389 | New | 0.04% | $0 M | Nov 13, 2026 |
| 58 | Prelude Capital Management, LLC | 27,775 | New | 0.04% | $0 M | Nov 16, 2026 |
| 59 | Barclays PLC | 25,904 | +20,065 (+343.64%) | 0.03% | $0 M | Nov 6, 2026 |
| 60 | Caitong International Asset Management Co., Ltd | 24,495 | -16,825 (-40.72%) | 0.03% | $0 M | Oct 29, 2026 |
| 61 | Price T Rowe Associates Inc /MD/ | 24,246 | 0 (0.00%) | 0.03% | $0 M | Nov 16, 2026 |
| 62 | Schonfeld Strategic Advisors LLC | 23,995 | New | 0.03% | $0 M | Nov 16, 2026 |
| 63 | Fielder Capital Group LLC | 22,822 | -81 (-0.35%) | 0.03% | $0 M | Nov 12, 2026 |
| 64 | Axq Capital, LP | 21,942 | +10,918 (+99.04%) | 0.03% | $0 M | Nov 12, 2026 |
| 65 | State of Wyoming | 21,342 | -2,140 (-9.11%) | 0.03% | $0 M | Oct 28, 2026 |
| 66 | AQR Capital Management LLC | 20,637 | -97,185 (-82.48%) | 0.03% | $0 M | Nov 16, 2026 |
| 67 | Composition Wealth, LLC | 19,851 | 0 (0.00%) | 0.03% | $0 M | Nov 10, 2026 |
| 68 | Tower Research Capital LLC (TRC) | 19,805 | +203 (+1.04%) | 0.03% | $0 M | Nov 16, 2026 |
| 69 | Vanguard Global Advisers, LLC | 16,453 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 70 | Perkins Capital Management Inc | 16,000 | New | 0.02% | $0 M | Nov 2, 2026 |
| 71 | WINTON GROUP Ltd | 15,200 | New | 0.02% | $0 M | Nov 12, 2026 |
| 72 | Two Sigma Investments, LP | 13,879 | New | 0.02% | $0 M | Nov 16, 2026 |
| 73 | Hudson Bay Capital Management LP | 11,030 | New | 0.01% | $0 M | Nov 13, 2026 |
| 74 | Russell Investments Group, Ltd. | 10,803 | +1,964 (+22.22%) | 0.01% | $0 M | Nov 6, 2026 |
| 75 | Persistent Asset Partners Ltd | 10,444 | New | 0.01% | $0 M | Nov 13, 2026 |
| 76 | IMC-Chicago, LLC | 10,316 | -4,250 (-29.18%) | 0.01% | $0 M | Nov 5, 2026 |
| 77 | Canton Hathaway, LLC | 10,000 | New | 0.01% | $0 M | Oct 23, 2026 |
| 78 | Jpmorgan Chase & Co | 4,097 | +3,349 (+447.73%) | 0.01% | $0 M | Nov 12, 2026 |
| 79 | FMR LLC | 3,451 | -1,610 (-31.81%) | 0.00% | $0 M | Nov 10, 2026 |
| 80 | BNP Paribas Financial Markets | 2,494 | -146,321 (-98.32%) | 0.00% | $0 M | Nov 12, 2026 |
| 81 | Royal Bank Of Canada | 2,449 | -8,709 (-78.05%) | 0.00% | $0 M | Nov 16, 2026 |
| 82 | Jones Financial Companies Lllp | 2,329 | New | 0.00% | $0 M | Nov 13, 2026 |
| 83 | Citigroup Inc | 2,313 | -306 (-11.68%) | 0.00% | $0 M | Nov 4, 2026 |
| 84 | Osaic Holdings, Inc. | 795 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 85 | Physician Wealth Advisors, Inc. | 775 | 0 (0.00%) | 0.00% | $0 M | Oct 20, 2026 |
| 86 | GAMMA Investing LLC | 681 | 0 (0.00%) | 0.00% | $0 M | Oct 8, 2026 |
| 87 | SBI Securities Co., Ltd. | 453 | -5 (-1.09%) | 0.00% | $0 M | Oct 22, 2026 |
| 88 | Wells Fargo & Company/mn | 150 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 89 | Transamerica Financial Advisors, LLC | 119 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 90 | Federation des caisses Desjardins du Quebec | 104 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 91 | PNC Financial Services Group, Inc. | 94 | -30 (-24.19%) | 0.00% | $0 M | Nov 6, 2026 |
| 92 | Robinhood Markets, Inc. | 64 | — | 0.00% | $0 M | Nov 18, 2026 |
| 93 | TD Waterhouse Canada Inc. | 59 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 94 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 24 | New | 0.00% | $0 M | Nov 16, 2026 |
| 95 | IFP Advisors, Inc | 7 | -5 (-41.67%) | 0.00% | $0 M | Oct 16, 2026 |
| 96 | EverSource Wealth Advisors, LLC | 6 | -600 (-99.01%) | 0.00% | $0 M | Nov 4, 2026 |
Mutual funds holding Neuronetics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 1.06 M | $1 M | 0.87% | <0.01% | −34% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 424,323 | $1 M | 0.35% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 217,184 | $0 M | 0.18% | <0.01% | −46% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 189,766 | $0 M | 0.16% | <0.01% | −2.9% | May 31, 2026 |
| 🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC | 95,205 | $0 M | 0.08% | 0.08% | no change | Jun 30, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 93,494 | $0 M | 0.08% | <0.01% | −0.5% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 87,050 | $0 M | 0.07% | <0.01% | −14% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 69,400 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT GAMCO Small Company Value PortfolioEquitable Investment Management Group, LLC | 75,000 | $0 M | 0.06% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 58,666 | $0 M | 0.05% | <0.01% | +6.9% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 45,586 | $0 M | 0.04% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 35,270 | $0 M | 0.03% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 AQR Small Cap Momentum Style FundAQR CAPITAL MANAGEMENT, LLC | 36,487 | $0 M | 0.03% | 0.03% | — | Mar 31, 2026 |
| 🇺🇸 The Gabelli Small Cap Growth FundGabelli Funds, LLC | 30,000 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 26,296 | $0 M | 0.02% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 19,442 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 7,545 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 6,433 | $0 M | <0.01% | <0.01% | −6.4% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 4,400 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 TETON Westwood Mighty Mites FundTeton Advisors, LLC | 5,000 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 2,941 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 1,750 | $0 M | <0.01% | <0.01% | +2.6% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 1,369 | $0 M | <0.01% | <0.01% | −44% | May 31, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 1,381 | $0 M | <0.01% | <0.01% | −43% | May 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 1,556 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 1,266 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 1,350 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC | 145 | $0 M | <0.01% | <0.01% | −27% | Jul 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 28 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Neuronetics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Glenn P. MuirDirector | Grant or award | +175,000 | $1.310 | $229 K | 576,816 | Form 4 |
| filed | Sasha CucuzDirector | Grant or awardindirect | +370,370 | $1.350 | $500 K | 995,370 | Form 4 |
| filed | Jorey Chernett10% owner | Sell | -2.19 M | $1.150 | $2.5 M | 7.33 M | Form 4 |
| filed | Sasha CucuzDirector | Otherindirect | +625,000 | $1.600 | $1.0 M | 625,000 | Form 4 |
| filed | Robert CascellaDirector | Grant or award | +128,242 | $1.500 | $192 K | 753,259 | Form 4 |
| filed | Robert CascellaDirector | Grant or award | +44,758 | $1.560 | $70 K | 798,017 | Form 4 |
| filed | Jorey Chernett10% owner | Sell | -706,840 | $1.430 | $1.0 M | 9.51 M | Form 4 |
| filed | Jorey Chernett10% owner | Sell | -86,757 | $1.610 | $140 K | 10.22 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Neuronetics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-28.99 reverse split
Trading halts
- 2025-08-05 15:33 UTC, code LUDP, resumed 15:38 UTC
Fails to deliver
- : 5,524 shares at $2.08
- : 1,392 shares at $2.01
- : 5,865 shares at $2.88
- : 1,000 shares at $2.80
- : 1,078 shares at $3.01
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Neuronetics, Inc. scorecard#
Passes 7 of the 22 checks that could be worked out: strongest in growth (4 of 6), weakest in valuation (1 of 5). Fiscal year 2025; market cap of Oct 23, 2026.
Valuation1 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' median7.2×Price to book 7.2× against Diagnostics and Research's median of 3.7×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-13.1%Free cash flow is -13.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 6
- ✓Revenue grew in the newest year99.2%Revenue up 99.2% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years31.8%31.8% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median31.8%31.8% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-0.59 vs -1.38Diluted EPS -0.59 in fiscal 2025 against -1.38 the year before (report's currency).
- ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$27 M in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability1 of 5
- ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-21.1%-21.1% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-155.7%-155.7% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-21.1%-21.1% in fiscal 2025 against -53.8% in 2022.
Financial health1 of 5
- ✓Short-term assets cover short-term liabilities2.0×Current ratio 2.02 at the end of fiscal 2025.
- ✗Debt below equity2.9×Debt to equity 2.94 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-4.1×Operating income -4.1 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-3.11Z-score -3.11 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year107.8%Diluted shares up 107.8% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Neuronetics, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -21.1% | -2.4% | |
| Net margin | -26.2% | -3.6% | |
| Return on equity | -155.7% | -5.4% | |
| Revenue growth, 3 years a year | 31.8% | 3.6% | |
| Revenue growth | 99.2% | 6.6% | |
| Debt to equity | 2.94× | 0.57× |
4of 9on the Piotroski tests of financial strength
- Net loss of $39 million, the 10th loss-making year in a row.
- Free cash flow was negative: -$21 million.
- The share count rose 107.8% in the year.
- Operating income covers the interest bill only -4.1 times.
Neuronetics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 149+99.2%100% | 75+5.0%100% | 71+9.4%100% | 65+17.9%100% | 55+12.3%100% | 49−21.4%100% | 63+18.7%100% | 53+30.5%100% | 40+18.1%100% | 34—100% | |
| Cost of revenue | 77+271%51.5% | 21+5.5%27.7% | 20+26.9%27.5% | 15+32.9%23.7% | 12+0.9%21.1% | 12−24.9%23.5% | 15+23.6%24.6% | 12+29.2%23.6% | 9.6+45.5%23.8% | 6.6—19.3% | |
| Gross profit | 72+33.5%48.5% | 54+4.8%72.3% | 52+4.0%72.5% | 50+13.9%76.3% | 44+15.8%78.9% | 38−20.3%76.5% | 47+17.2%75.4% | 40+30.9%76.4% | 31+11.6%76.2% | 28—80.7% | |
| Research and development | 6.6−48.4%4.4% | 13+34.2%17.1% | 9.5+1.9%13.3% | 9.3+17.8%14.3% | 7.9−13.9%14.3% | 9.2−33.1%18.7% | 14+67.0%21.9% | 8.2+3.7%15.6% | 7.9−3.5%19.6% | 8.2—24.0% | |
| Selling and marketing | 47+4.0%31.8% | 46−3.6%60.9% | 47−5.3%66.3% | 50+32.4%76.7% | 38+15.9%68.2% | 33−24.3%66.1% | 43+12.4%68.6% | 38+37.1%72.5% | 28+28.0%69.0% | 22—63.7% | |
| General and administrative | 50+63.9%33.3% | 30+19.3%40.5% | 25−0.4%35.6% | 26−0.1%39.1% | 26+40.1%46.2% | 18+4.5%37.0% | 17+27.7%27.9% | 14+59.4%25.9% | 8.6+23.8%21.2% | 6.9—20.2% | |
| Operating expenses | 104+16.9%69.6% | 89+7.9%118% | 82−3.0%115% | 85+19.1%130% | 71+18.7%129% | 60−19.1%122% | 74+23.3%118% | 60+35.5%114% | 44+20.2%110% | 37—108% | |
| Operating income | −31—−21.1% | −35—−46.2% | −31—−42.8% | −35—−53.8% | −28—−49.8% | −22—−45.3% | −27—−43.0% | −20—−37.6% | −14—−33.7% | −9.3—−27.3% | |
| Interest expense and finance costs | 8.4+15.5%5.6% | 7.3+34.3%9.7% | 5.4+27.6%7.6% | 4.3+5.8%6.5% | 4.0−11.1%7.3% | 4.5+22.7%9.2% | 3.7−0.1%5.9% | 3.7+31.3%7.0% | 2.8+53.0%6.9% | 1.8—5.4% | |
| Other non-operating income (expense) | 0.7−71.9%0.5% | 2.5−56.0%3.4% | 5.8+163%8.1% | 2.2+465%3.4% | 0.4+29.1%0.7% | 0.3−80.8%0.6% | 1.6—2.5% | −0.6−261%−1.1% | 0.4—0.9% | −0.1—−0.2% | |
| Income before tax | — | — | — | — | — | — | −29—−46.3% | −24—−45.7% | −16—−39.8% | −11—−32.7% | |
| Net income including minority interests | −39—−26.2% | −44—−58.4% | −30—−42.3% | −37—−57.0% | −31—−56.4% | −27—−55.7% | −29—−46.4% | −24—−45.7% | −16—−39.7% | −11—−32.8% | |
| Minority interests' share of net income | −0.1—−0.1% | −0.0—−0.0% | — | — | — | — | — | — | — | — | |
| Net income attributable to shareholders | −39—−26.1% | −44—−58.4% | −30—−42.3% | −37—−57.0% | −31—−56.4% | −27—−55.7% | −29—−46.4% | −24—−45.7% | −16—−39.7% | −11—−32.8% | |
| Earnings per share, basic | -0.59—— | -1.38—— | -1.05—— | -1.38—— | -1.22—— | -1.46—— | -1.58—— | -2.69—— | -86.34—— | -76.95—— | |
| Earnings per share, diluted | -0.59—— | -1.38—— | -1.05—— | -1.38—— | -1.22—— | -1.46—— | -1.58—— | -2.69—— | -86.34—— | -76.95—— | |
| Shares, weighted average (basic) | 66+108%— | 32+10.7%— | 29+6.5%— | 27+5.6%— | 25+35.3%— | 19+2.5%— | 18—— | — | — | — | |
| Shares, weighted average (diluted) | 66+108%— | 32+10.7%— | 29+6.5%— | 27+5.6%— | 25+35.3%— | 19+2.5%— | 18+105%— | 8.9+4711%— | 0.2+27.4%— | 0.1—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 28+52.4%19.9% | 18−69.1%13.1% | 60−15.2%51.5% | 70−25.3%60.2% | 94+92.3%66.7% | 49−35.3%62.2% | 76−27.6%75.6% | 105+259%89.4% | 29+71.1%74.9% | 17—— | |
| Receivables | 16−29.5%11.6% | 23+48.0%16.6% | 16+16.1%13.6% | 14+76.4%11.6% | 7.7+7.5%5.5% | 7.2+9.1%9.1% | 6.6+16.9%6.6% | 5.6+31.7%4.8% | 4.3—11.0% | — | |
| Inventory | 4.3+1.9%3.1% | 4.2−47.5%3.0% | 8.1−9.1%7.0% | 8.9+35.6%7.6% | 6.6+76.4%4.6% | 3.7+34.1%4.7% | 2.8+14.1%2.8% | 2.4−1.5%2.1% | 2.5—6.3% | — | |
| Other current assets | 2.9−57.3%2.1% | 6.8+43.6%4.9% | 4.8+119%4.1% | 2.2−29.6%1.9% | 3.1+41.4%2.2% | 2.2+19.5%2.8% | 1.8−0.4%1.8% | 1.8+63.7%1.6% | 1.1—2.9% | — | |
| Current assets | 62+5.9%43.5% | 58−38.0%41.2% | 94−5.0%81.0% | 99−14.4%84.5% | 115+77.4%81.7% | 65−26.5%82.7% | 88−22.7%88.3% | 114+209%97.8% | 37—95.0% | — | |
| Property, plant and equipment | 4.5−28.5%3.2% | 6.2+211%4.4% | 2.0+0.9%1.7% | 2.0+63.2%1.7% | 1.2+67.1%0.9% | 0.7−34.1%0.9% | 1.1−19.7%1.1% | 1.4+1.4%1.2% | 1.4—3.5% | — | |
| Right-of-use (leased) assets | 24−13.0%16.6% | 27+877%19.2% | 2.8−16.7%2.4% | 3.3−14.3%2.8% | 3.9+13.6%2.8% | 3.4−10.0%4.3% | 3.8—3.8% | — | — | — | |
| Goodwill | 24+26.8%16.7% | 19—13.2% | — | — | — | — | — | — | — | — | |
| Other intangible assets | 18−7.4%12.8% | 20—13.9% | — | — | — | — | — | — | — | — | |
| Total assets | 142+0.5%100% | 141+21.6%100% | 116−0.9%100% | 117−17.2%100% | 141+79.5%100% | 79−21.5%100% | 100−14.4%100% | 117+201%100% | 39—100% | — | |
| Accounts payable | 11−3.1%7.6% | 11+133%7.9% | 4.8+95.3%4.1% | 2.4−43.4%2.1% | 4.3+14.7%3.0% | 3.7−18.9%4.8% | 4.6+23.1%4.6% | 3.8+49.5%3.2% | 2.5—6.5% | — | |
| Debt due within a year | — | — | — | 13—11.2% | — | — | 11—11.2% | — | 0—0.0% | — | |
| Current liabilities | 31−2.4%21.6% | 31+57.8%22.2% | 20−40.3%17.1% | 33+111%28.4% | 16+14.8%11.1% | 14−50.6%17.4% | 28+104%27.6% | 14+13.0%11.6% | 12—30.8% | — | |
| Long-term debt | 66+19.3%46.5% | 55−7.0%39.1% | 59+160%51.2% | 23−35.4%19.5% | 35+2.1%25.0% | 35+74.0%44.0% | 20−34.5%19.9% | 30+2.8%26.0% | 30—75.9% | — | |
| Lease liabilities (non-current) | 19−16.5%13.4% | 23+867%16.1% | 2.3−20.9%2.0% | 3.0−16.2%2.5% | 3.5+13.4%2.5% | 3.1+19.2%4.0% | 2.6—2.6% | — | — | — | |
| Total liabilities | 115+5.7%81.5% | 109+33.6%77.4% | 82+36.5%70.5% | 60+6.7%51.2% | 56+5.4%39.7% | 53+1.6%67.6% | 52+13.8%52.2% | 46+3.4%39.3% | 44—114% | — | |
| Retained earnings | −459—−324% | −420—−298% | −376—−325% | −346—−296% | −309—−219% | −278—−353% | −250—−250% | −221—−189% | −197—−506% | — | |
| Shareholders' equity | 22−19.2%15.8% | 28−19.0%19.7% | 34−40.1%29.5% | 57−33.0%48.8% | 85+234%60.3% | 25−46.7%32.4% | 48−32.6%47.8% | 71—60.7% | −193—−495% | −177—— | |
| Minority interests | 3.9−5.6%2.7% | 4.1—2.9% | — | — | — | — | — | — | — | — | |
| Total equity | 26−17.5%18.5% | 32−7.0%22.6% | 34−40.1%29.5% | 57−33.0%48.8% | 85—60.3% | — | — | — | — | — | |
| Total liabilities and equity | 142+0.5%100% | 141+21.6%100% | 116−0.9%100% | 117−17.2%100% | 141+79.5%100% | 79−21.5%100% | 100−14.4%100% | 117+201%100% | 39—100% | — | |
| Shares outstanding | 69+23.9%— | 56+91.4%— | 29+6.7%— | 27+3.3%— | 26+38.1%— | 19+2.5%— | 19+5.1%— | 18+7581%— | 0.2—— | — | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 3.5+67.1%2.3% | 2.1+3.3%2.8% | 2.0+21.7%2.8% | 1.6+55.5%2.5% | 1.1+12.6%1.9% | 0.9−11.6%1.9% | 1.1+20.7%1.7% | 0.9+48.0%1.7% | 0.6−11.4%1.5% | 0.7—2.0% | |
| Share-based compensation | 6.8+22.2%4.6% | 5.6−23.5%7.5% | 7.3−16.3%10.3% | 8.7+11.1%13.4% | 7.9+78.7%14.2% | 4.4+28.2%8.9% | 3.4+97.0%5.5% | 1.7+251%3.3% | 0.5+208%1.2% | 0.2—0.5% | |
| Cash from operating activities | −20—−13.7% | −31—−41.4% | −32—−44.9% | −31—−47.1% | −28—−50.6% | −28—−57.7% | −30—−48.6% | −21—−39.0% | −11—−27.6% | −8.5—−25.0% | |
| Capital expenditure | −0.8—−0.5% | −1.5—−2.0% | −2.4—−3.3% | −3.3—−5.0% | −2.4—−4.3% | −0.7—−1.5% | −0.8—−1.3% | −1.0—−1.9% | −0.6—−1.5% | −0.3—−0.9% | |
| Acquisitions, net of cash acquired | — | −2.6—−3.4% | — | — | — | — | — | — | — | — | |
| Cash from investing activities | −0.8—−0.5% | −2.4—−3.2% | −1.3−120%−1.9% | 6.7—10.3% | −9.8—−17.8% | −0.7—−1.5% | −0.8—−1.3% | −1.0—−1.9% | −0.6—−1.5% | −0.3—−0.9% | |
| Debt issued | 10−82.6%6.7% | 57+130%76.8% | 25—35.0% | — | — | 41—84.0% | — | — | — | — | |
| Debt repaid | — | −60—−80.1% | −1.2—−1.7% | — | — | −39—−78.9% | — | — | — | — | |
| Shares issued | — | — | — | — | 81—146% | — | — | — | — | — | |
| Cash from financing activities | 36—24.0% | −6.8−130%−9.1% | 23+10865%31.8% | 0.2−99.8%0.3% | 83+3404%150% | 2.4−2.1%4.8% | 2.4−97.5%3.9% | 97+307%184% | 24+387%59.0% | 4.9—14.3% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 160+23.0%100% | 42+12.5%100% | 42+9.1%100% | 34+7.8%100% | 42*+85.7%100% | 37+101%100% | 38+132%100% | 32+83.6%100% | 22*+10.7%100% | 19—100% | 16—100% | 17—100% | 20*—100% | |
| Cost of revenue | 79+22.4%49.3% | 20−0.6%47.8% | 20−0.0%48.9% | 18+12.7%53.1% | 20*+164%48.0% | 20+346%54.1% | 20+376%53.4% | 16+275%50.8% | 7.6*+67.3%33.8% | 4.5—24.4% | 4.3—26.0% | 4.3—24.9% | 4.5*—22.4% | |
| Gross profit | 81+23.6%50.7% | 22+28.0%52.2% | 21+19.5%51.1% | 16+2.6%46.9% | 22*+45.7%52.0% | 17+22.2%45.9% | 18+45.8%46.6% | 16+20.2%49.2% | 15*−5.6%66.2% | 14—75.6% | 12—74.0% | 13—75.1% | 16*—77.6% | |
| Research and development | 5.6−48.0%3.5% | 1.2−20.9%2.8% | 1.3−25.7%3.2% | 1.4−15.6%4.0% | 1.7*−71.1%4.0% | 1.5−37.7%4.0% | 1.8−19.6%4.7% | 1.6−31.2%5.1% | 5.8*+162%25.7% | 2.4—13.0% | 2.2—13.6% | 2.3—13.5% | 2.2*—10.9% | |
| Selling and marketing | 41−10.1%25.6% | 8.5−28.4%20.2% | 10.0−15.9%24.0% | 11−10.5%31.2% | 12*+19.7%28.1% | 12−0.2%31.8% | 12−3.5%31.1% | 12+3.1%37.5% | 9.8*−16.3%43.6% | 12—64.1% | 12—74.8% | 12—66.8% | 12*—57.7% | |
| General and administrative | 49+4.9%31.0% | 12+5.4%27.8% | 11−6.1%27.4% | 13−0.7%37.9% | 13*+23.7%31.9% | 11+49.0%29.7% | 12+97.6%31.9% | 13+121%41.1% | 11*+71.8%47.9% | 7.4—40.1% | 6.1—37.4% | 6.0—34.2% | 6.3*—30.9% | |
| Operating expenses | 96−7.2%60.1% | 21−12.6%50.9% | 23−12.0%54.7% | 25−6.0%73.0% | 27*+1.4%64.0% | 24+12.4%65.5% | 26+24.8%67.7% | 27+34.1%83.7% | 26*+30.5%117% | 22—117% | 21—126% | 20—115% | 20*—99.4% | |
| Operating income | −15—−9.4% | 0.5—1.3% | −1.5—−3.6% | −9.0—−26.1% | −5.0*—−12.1% | −7.3—−19.6% | −8.1—−21.1% | −11—−34.4% | −11*—−51.0% | −7.7—−41.7% | −8.5—−51.7% | −6.9—−39.4% | −4.4*—−21.8% | |
| Interest expense and finance costs | 8.6+9.9%5.4% | 2.1−2.8%5.1% | 2.1+7.9%5.1% | 2.3+17.9%6.6% | 2.1*+19.5%5.0% | 2.2+27.9%5.9% | 2.0−0.5%5.2% | 1.9+5.3%6.0% | 1.8*−4.7%7.8% | 1.7—9.3% | 2.0—12.0% | 1.8—10.5% | 1.8*—9.1% | |
| Other non-operating income (expense) | 1.4+24.8%0.9% | 0.0−62.7%0.1% | 0.2−13.8%0.4% | 1.0+313%3.0% | 0.2*−71.7%0.4% | 0.1−76.6%0.3% | 0.2−71.2%0.5% | 0.2−69.6%0.8% | 0.5*−38.7%2.4% | 0.5—2.9% | 0.7—4.0% | 0.8—4.7% | 0.9*—4.4% | |
| Net income including minority interests | −23—−14.4% | −1.6—−3.7% | −3.5—−8.3% | −11—−31.3% | −7.2*—−17.2% | −9.4—−25.2% | −9.8—−25.8% | −13—−39.7% | −13*—−56.4% | −13—−72.0% | −9.8—−59.8% | −7.9—−45.2% | −5.4*—−26.5% | |
| Minority interests' share of net income | 0.1—0.0% | 0.1—0.3% | −0.0−109%−0.1% | 0.0—0.0% | −0.0*—−0.1% | −0.4—−1.0% | 0.3—0.7% | −0.0—−0.0% | — | — | — | — | — | |
| Net income attributable to shareholders | −23—−14.4% | −1.7—−4.0% | −3.4—−8.3% | −11—−31.3% | −7.2*—−17.1% | −9.0—−24.3% | −10—−26.6% | −13—−39.6% | −13*—−56.3% | −13—−72.0% | −9.8—−59.8% | −7.9—−45.2% | −5.4*—−26.5% | |
| Earnings per share, basic | — | -0.02—— | -0.05—— | -0.16—— | — | -0.13—— | -0.15—— | -0.21—— | — | -0.44—— | -0.33—— | -0.27—— | — | |
| Earnings per share, diluted | — | -0.02—— | -0.05—— | -0.16—— | — | -0.13—— | -0.15—— | -0.21—— | — | -0.44—— | -0.33—— | -0.27—— | — | |
| Shares, weighted average (basic) | 77+14.4%— | 77+14.4%— | 73+10.5%— | 70+13.2%— | — | 67+122%— | 66+120%— | 61+109%— | — | 30—— | 30—— | 29—— | — | |
| Shares, weighted average (diluted) | 77+14.4%— | 77+14.4%— | 73+10.5%— | 70+13.2%— | — | 67+122%— | 66+120%— | 61+109%— | — | 30—— | 30—— | 29—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 22—16.8% | 22−21.0%16.8% | 19+75.0%14.6% | 13−34.7%10.5% | 28+52.4%19.9% | 28+34.0%19.2% | 11−74.3%8.1% | 20−57.6%14.2% | 18−69.1%13.1% | 21—28.2% | 43—44.0% | 48—46.0% | 60—51.5% | |
| Receivables | 14—10.9% | 14−22.8%10.9% | 16−38.9%12.1% | 16−39.7%12.6% | 16−29.5%11.6% | 19+11.1%12.9% | 26+52.3%19.4% | 26+49.7%18.4% | 23+48.0%16.6% | 17—22.7% | 17—17.7% | 18—16.9% | 16—13.6% | |
| Inventory | 4.9—3.7% | 4.9+14.4%3.7% | 5.5+11.3%4.2% | 4.7+15.9%3.8% | 4.3+1.9%3.1% | 4.3−12.9%3.0% | 4.9−19.5%3.7% | 4.1−39.2%2.9% | 4.2−47.5%3.0% | 5.0—6.7% | 6.1—6.3% | 6.7—6.4% | 8.1—7.0% | |
| Other current assets | 3.5—2.6% | 3.5−3.4%2.6% | 3.5−7.0%2.7% | 4.1−20.1%3.3% | 2.9−57.3%2.1% | 3.6−25.2%2.5% | 3.8−0.6%2.8% | 5.2+18.3%3.6% | 6.8+43.6%4.9% | 4.8—6.5% | 3.8—3.9% | 4.4—4.2% | 4.8—4.1% | |
| Current assets | 54—40.8% | 54−17.0%40.8% | 53−5.2%40.5% | 47−22.2%37.6% | 62+5.9%43.5% | 65+21.4%44.6% | 56−25.6%41.7% | 61−25.9%42.7% | 58−38.0%41.2% | 53—72.1% | 76—78.0% | 82—78.9% | 94—81.0% | |
| Property, plant and equipment | 3.2—2.4% | 3.2−35.5%2.4% | 3.5−34.9%2.6% | 3.9−33.7%3.1% | 4.5−28.5%3.2% | 4.9+201%3.4% | 5.3+208%4.0% | 5.8+217%4.1% | 6.2+211%4.4% | 1.6—2.2% | 1.7—1.8% | 1.8—1.8% | 2.0—1.7% | |
| Right-of-use (leased) assets | 25—18.7% | 25+1.9%18.7% | 24−2.3%18.2% | 23−13.6%18.4% | 24−13.0%16.6% | 24+941%16.7% | 24+887%18.2% | 27+916%18.8% | 27+877%19.2% | 2.3—3.1% | 2.5—2.6% | 2.6—2.5% | 2.8—2.4% | |
| Goodwill | 24—17.9% | 24+4.2%17.9% | 24+23.8%18.0% | 24+26.8%18.8% | 24+26.8%16.7% | 23—15.6% | 19—14.2% | 19—13.1% | 19—13.2% | — | — | — | — | |
| Other intangible assets | 17—12.9% | 17−7.9%12.9% | 17−7.7%13.2% | 18−7.6%14.2% | 18−7.4%12.8% | 19—12.7% | 19—14.0% | 19—13.6% | 20—13.9% | — | — | — | — | |
| Total assets | 132—100% | 132−9.3%100% | 132−2.3%100% | 125−11.7%100% | 142+0.5%100% | 145+96.3%100% | 135+39.1%100% | 142+36.8%100% | 141+21.6%100% | 74—100% | 97—100% | 104—100% | 116—100% | |
| Accounts payable | 10.0—7.6% | 10.0−13.9%7.6% | 12+27.7%9.4% | 11+34.8%9.1% | 11−3.1%7.6% | 12+251%8.0% | 9.7+137%7.2% | 8.5+185%6.0% | 11+133%7.9% | 3.3—4.4% | 4.1—4.2% | 3.0—2.9% | 4.8—4.1% | |
| Debt due within a year | — | — | — | — | — | — | — | — | — | — | 14—14.1% | — | — | |
| Current liabilities | 27—20.4% | 27−7.2%20.4% | 28+1.8%21.5% | 28+13.9%22.5% | 31−2.4%21.6% | 29+71.3%19.9% | 28−5.0%20.6% | 25+71.3%17.5% | 31+57.8%22.2% | 17—22.8% | 29—30.2% | 14—14.0% | 20—17.1% | |
| Long-term debt | 62—46.8% | 62−6.0%46.8% | 62+10.8%46.8% | 61+10.8%48.9% | 66+19.3%46.5% | 66+42.8%45.1% | 56+20.4%41.2% | 55−6.9%39.0% | 55−7.0%39.1% | 46—62.1% | 46—47.7% | 59—57.3% | 59—51.2% | |
| Lease liabilities (non-current) | 21—15.9% | 21+7.4%15.9% | 20+0.3%15.1% | 19−16.2%14.9% | 19−16.5%13.4% | 19+964%13.4% | 20+886%14.7% | 22+922%15.7% | 23+867%16.1% | 1.8—2.5% | 2.0—2.1% | 2.2—2.1% | 2.3—2.0% | |
| Total liabilities | 110—83.0% | 110−4.0%83.0% | 110+6.5%83.5% | 108+5.8%86.4% | 115+5.7%81.5% | 114+76.3%78.4% | 103+33.2%76.6% | 102+34.5%72.2% | 109+33.6%77.4% | 65—87.3% | 77—80.0% | 76—73.4% | 82—70.5% | |
| Retained earnings | −475—−360% | −475—−360% | −473—−360% | −470—−374% | −459—−324% | −452—−310% | −443—−329% | −432—−305% | −420—−298% | −407—−549% | −394—−407% | −384—−370% | −376—−325% | |
| Shareholders' equity | 19—14.2% | 19−31.6%14.2% | 18−34.2%13.6% | 13−62.6%10.6% | 22−19.2%15.8% | 27+192%18.8% | 27+40.0%20.2% | 35+28.2%25.0% | 28−19.0%19.7% | 9.4—12.7% | 19—20.0% | 28—26.6% | 34—29.5% | |
| Minority interests | 3.7—2.8% | 3.7−7.7%2.8% | 3.8−13.1%2.9% | 3.8−7.0%3.0% | 3.9−5.6%2.7% | 4.0—2.8% | 4.4—3.2% | 4.1—2.9% | 4.1—2.9% | — | — | — | — | |
| Total equity | 22—17.0% | 22−28.6%17.0% | 22−31.3%16.5% | 17−56.8%13.6% | 26−17.5%18.5% | 31+234%21.6% | 32+62.5%23.4% | 40+42.9%27.8% | 32−7.0%22.6% | 9.4—12.7% | 19—20.0% | 28—26.6% | 34—29.5% | |
| Total liabilities and equity | 132—100% | 132−9.3%100% | 132−2.3%100% | 125−11.7%100% | 142+0.5%100% | 145+96.3%100% | 135+39.1%100% | 142+36.8%100% | 141+21.6%100% | 74—100% | 97—100% | 104—100% | 116—100% | |
| Shares outstanding | 78—— | 78+13.6%— | 76+15.2%— | 70+5.7%— | 69+23.9%— | 68+126%— | 66+119%— | 66+120%— | 56+91.4%— | 30—— | 30—— | 30—— | 29—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 2.2−6.2%1.4% | 0.3−40.0%0.7% | 0.4−20.0%1.0% | 0.7−18.2%2.2% | 0.8*+72.0%1.8% | 0.50.0%1.3% | 0.5−16.7%1.3% | 0.9+62.7%2.8% | 0.4*−11.3%2.0% | 0.5—2.7% | 0.6—3.6% | 0.6—3.2% | 0.5*—2.5% | |
| Share-based compensation | 4.7−20.6%3.0% | 0.2−87.4%0.4% | 0.7−62.1%1.7% | 1.7+16.1%4.9% | 2.2*+70.1%5.2% | 1.4−0.7%3.8% | 1.8+16.1%4.8% | 1.4+7.9%4.5% | 1.3*−21.2%5.7% | 1.4—7.7% | 1.6—9.5% | 1.3—7.7% | 1.6*—8.0% | |
| Cash from operating activities | −8.3—−5.2% | 1.2*—3.0% | −1.0*—−2.4% | −9.4—−27.3% | 0.9*—2.2% | −0.8*—−2.1% | −3.5*—−9.2% | −17—−53.1% | −8.6*−503%−38.2% | −5.4*—−29.2% | −5.0*—−30.2% | −12—−69.0% | 2.1*—10.5% | |
| Capital expenditure | −1.3—−0.8% | −0.5*—−1.1% | −0.4*—−1.0% | −0.2—−0.6% | −0.2*—−0.5% | −0.1*—−0.3% | −0.3*—−0.7% | −0.2—−0.7% | −0.1*—−0.4% | −0.4*—−2.1% | −0.6*—−3.7% | −0.4—−2.2% | −0.9*—−4.3% | |
| Cash from investing activities | −1.3—−0.8% | −0.5*—−1.1% | −0.4*—−1.0% | −0.2—−0.5% | −0.2*—−0.5% | −0.1*−914%−0.3% | −0.3*—−0.7% | −0.2−422%−0.7% | −2.4*—−10.6% | 0.0*—0.1% | −0.1*—−0.7% | 0.1—0.4% | −0.6*—−2.8% | |
| Debt issued | — | — | — | — | 0*−100%0.0% | — | — | — | 9.4*−58.2%41.8% | — | — | — | 23*—111% | |
| Debt repaid | — | 0*—0.0% | 0*—0.0% | −5.0—−14.5% | — | — | — | — | 0*—0.0% | — | — | — | 0*—0.0% | |
| Shares issued | — | — | — | — | — | — | 0*—0.0% | 21—64.7% | — | — | — | — | — | |
| Cash from financing activities | 2.9−93.7%1.8% | 2.1*−88.0%5.1% | 7.4*+740700%17.8% | −5.6−129%−16.2% | −1.0*−111%−2.5% | 18*—48.0% | 0.0*—0.0% | 19—59.3% | 9.6*−57.0%42.5% | — | — | — | 22*—110% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Neuronetics, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Service(total)$87 M58%+1859%
- Products and Other(total)$62 M42%-12%
Business segments
- Clinical Services$87 M58%+1859%
- Medical Device$62 M42%-12%
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Neuronetics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Sullivan | $4.4 M | $2.2 M | $2.2 M | $20 |
| 2024Mr. Sullivan | $2.4 M | $1.8 M | $1.1 M | $14 |
| 2023Mr. Sullivan | $3.0 M | −$1.9 M | $1.3 M | $26 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Neuronetics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 13 · Material agreement 9 · Unregistered share sale 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 11
| Filed | What happened | Filing |
|---|---|---|
| Material agreement | 8-K | |
| Material agreement | 8-K/A | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| RestructuringDirectors and officersMaterial agreement | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Directors and officersResults announced | 8-K | |
| Material agreementResults announced | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Directors and officersResults announced | 8-K | |
| Results announced | 8-K/A | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
1 acquisitions, $39 M paid where reported · 5 private funding rounds before listing
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| Greenbrook | 2024 | — | $39 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jun 2017 | $15 M | No. 5 | $10 to $50 million | 22 | equity | SEC |
| Apr 2015 | $34 M | No. 4 | $10 to $50 million | 23 | equity | SEC |
| Nov 2014 | $9 M | No. 3 | $2 to $10 million | 23 | options | SEC |
| May 2011 | $30 M | No. 2 | $10 to $50 million | 22 | equity | SEC |
| Aug 2009 | $30 M | No. 1 | $10 to $50 million | 17 | equity | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Neuronetics, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2025.
Lobbying firms hired in 2025
CHECKMATE GOVERNMENT RELATIONS
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $0 | — | 3 |
| 2025 | $0 | — | 1 |
| 2024 | $90 K | — | 3 |
| 2023 | $75 K | — | 2 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Neuronetics Inc.” and “Neuronetics, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | · | · | · | · | · | · | · | · | · | · | · | — | |
| 2024 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| 2020 | · | · | · | · | · | · | · | · | · | · | · | · | — |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| 5% of workforce | Restructuring planSEC 8-K | “On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees.” | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing | |
| Not stated | Restructuring planSEC 8-K | Company-wide plan | Filing |
Source: State WARN notices and SEC 8-K item 2.05
How Neuronetics, Inc. compares in Diagnostics and Research
- Market cap$162 M · higher than 30% of 110
- Revenue$149 M · higher than 40% of 123
- Net margin-14.4% · higher than 28% of 112
- Revenue growth99.2% · higher than 93% of 89
- Price / sales1.0× · lower than 86% of 85
- Price / book7.2× · lower than 27% of 84
- FCF yield-13.1% · higher than 26% of 66
- 🇺🇸 MaxCyte, Inc.$156 M
- 🇨🇦 Spectral Medical Inc.$217 M
- 🇺🇸 Exagen Inc.$218 M
- 🇮🇩 PT Prodia Widyahusada Tbk$119 M
- 🇺🇸 Anixa Biosciences, Inc.$117 M
- 🇮🇳 Vimta Labs Limited$226 M
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Neuronetics, Inc.🇺🇸 | $162 M | — | -14.4% | +99.2% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- MaxCyte, Inc.$156 M
- Spectral Medical Inc.$217 M
- Exagen Inc.$218 M
- PT Prodia Widyahusada Tbk$119 M
- Anixa Biosciences, Inc.$117 M
- Vimta Labs Limited$226 M
Sources and freshness
- Market cap:
- Oct 23, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Neuronetics, Inc.? Verify and update this profile — free
Show Neuronetics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.